Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aytu BioPharma (NASDAQ:AYTU) reported Q3 2024 GAAP EPS of $(0.52), beating the estimate of $(0.64). Sales were $17.993M, also surpassing the $17.346M estimate. Despite the beats, sales decreased by 20.85% year-over-year.
May 15, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aytu BioPharma reported better-than-expected Q3 2024 EPS and sales, but sales decreased significantly year-over-year.
The better-than-expected EPS and sales figures are positive for AYTU in the short term, but the significant year-over-year sales decline may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100